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Background/objectives:Mineralocorticoid receptor antagonist (MRA) use in acutely decompensated chronic heart
failure (ADCHF) may improve congestion through diuretic effect and prevent neurohormonal activation. We
aimed to evaluate the clinical effect and safety of spironolactone in ADCHF.
Methods: Prospective, experimental, single-center, and single-blinded trial. Patients were treated with: standard
ADCHF therapy or oral spironolactone 50–100 mg/d plus standard ADCHF therapy.
Results: During a 1 year period, 100 patients were enrolled, 50 included in the treatment group. Mean (SD)
spironolactone dose (mg) at day 1was 94.5 ± 23.3 and at day 3was 62.7 ± 24.3.Worsening renal function (in-
crease in pCr ≥ 0.3 mg/dL fromday 1 today 3)wasmore likely to occur in control group (20%vs. 4%; p = 0.038),
serum potassium did not differ between groups, and plasma NTproBNP had a signiﬁcant decrease in
spironolactone group at day 3 (median [IQR], 2488 [4579] vs. 1555 [1832]; p = 0.05). Furthermore, a greater
proportion of patients in the treatment groupwere free of congestion at day 3: less edema, rales, jugular venous
pressure (JVP) and orthopnea (all, p b 0.05). In addition, a signiﬁcantly higher proportion of patients were on
oral furosemide at day 3 (44% vs. 82%; p b 0.001).
Conclusions: Our study supports the safety of high dose spironolactone in ADCHF and suggests a positive impact
in the resolution of congestion. The important ﬁndings of our pilot study need to be conﬁrmed in larger trials.© 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
The recognition of the importance of chronic neurohormonal activa-
tion in heart failure (HF) pathophysiologywas crucial to the development
of new therapies beyond diuretics and digoxin. Pharmacological inhibi-
tion of renin–angiotensin–aldosterone system (RAAS) had a remarkable
impact onmorbidity andmortality of HF patients [1]. Likewise, mineralo-
corticoid receptor antagonists (MRAs) showed to be effective in reducing
hospitalizations and mortality in systolic HF [2,3].
The natural history of HF is characterized by recurrent episodes of
acute HF (AHF). AHF deﬁnes a new onset HF or acutely decompensated
chronic HF (ADCHF). Patients present with signs and symptoms needing
urgent therapy [4]. Despite the prominent therapeutic advances in ambu-
latory HF patient, little progress has been made in the improvement of
ADCHF patient treatment [5].
Aldosterone levels are elevated in patients with ADCHF despite the
use of angiotensin-converting enzyme inhibitors (ACEi), angiotensin re-
ceptor blockers (ARB), and beta-blockers (BB) [6]. In this setting, aldoste-
rone elevation may contribute to cardiorenal dysfunction, increasing theInternal Medicine Department,
+351 222077500; fax: +351
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ion of Internal Medicine. Published b
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.2013.08.711risk of death and ventricular arrhythmias [6–8]. Therefore, MRA use
in ADCHF treatment has two major putative advantages: improve
congestion and hypervolemia through its diuretic effect and prevent
the neurohormonal activation that characterizes ADCHF, and that is en-
hanced by loop diuretics [5,9,10].
The impact of MRAs in ADCHF patients has not been well-studied.
We aimed to evaluate the short-term clinical effect and safety of the
MRA antagonist spironolactone in worsening chronic HF patients.
2. Methods
2.1. Study design
Prospective, experimental, single-center, and single-blinded trial
conducted in a Portuguese tertiary hospital enrolling participants between
February 2012 and February 2013.
2.2. Study participants
Patients were eligible for enrollment if they presented with decom-
pensation of chronic HF with symptoms leading to hospitalization. HF
was diagnosed on the basis of the presence of history of chronic heart fail-
ure and at least one symptom (dyspnea, orthopnea, or edema) and one
sign (rales, peripheral edema, ascites, or pulmonary vascular congestiony Elsevier B.V. All rights reserved.
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cardiac surgery within 60 days of enrollment, cardiac mechanical
support, cardiac resynchronization-therapy within the last 60 days, co-
morbid conditions with an expected survival of less than 6 months,
acute myocardial infarction at time of hospitalization, hemodynamically
signiﬁcant uncorrected primary cardiac valvular disease, patients requir-
ing intravenous vasodilators or inotropic agents, supine systolic arterial
blood pressure b90 mmHg, serum creatinine level N1.5 mg/dL, serum
potassium level N5.0 mmol/L, hemoglobin level b9 g/dL, and sepsis.
Institutional review board or ethics committee approval was
obtained. All patients provided written informed consent to participate
in the study.
2.3. Treatment assignments
Patientswere non-randomly assigned in a sequential 1:1 ratio to the
intervention or standard treatment. Chief investigator was responsible
to assess the eligibility criteria and to allocate the intervention after
being contacted by the patient assistant physician. Patients were
blinded to the intervention allocation. Assistant physicians were not
blinded to intervention allocation. Assistant physicians were Attending
Physicians or Fellows of Internal Medicine or Cardiology depending on
the ward where each patient was admitted. The assistant physicians
evaluated the clinical signs and symptoms and registered their
evaluation in the clinical diaries and then transcribed to our database
by the authors.
2.4. Trial Intervention
Patients were assigned to either oral spironolactone (minimum and
maximum initial dose of 50–100 mg/d, according to assistant physi-
cian) plus standard AHF therapy or standard AHF therapy alone.
Standard AHF therapy included intra-venous (i.v.) furosemide (bolus or
continuous infusion), digoxin, ACEi, ARB, nitrates, and/or non-invasive
ventilation (NIV), according to attending physician. At day 2, the attend-
ing physician had the option of adjusting spironolactone dose on the
basis of the clinical judgment and laboratory results. At this time, the
physician could decrease the dose by 50%, to a minimum of 50 mg/d, or
maintain the same strategy.
2.5. Study assessments
Patient's clinical status was prospectively recorded, by the assistant
physicians, according to previous deﬁned parameters.
An assessment of biomarkers, including plasma creatinine (pCr),
ions, N-terminal pro-brain natriuretic peptide (NTproBNP), high
sensitivity troponin T (hsTnT) and microalbuminuria was performed
at a central core laboratory at admission day (day 1) and day 3. Clinical
assessment and routine analyses were performed daily during hospital
stay. All patients performed a transthoracic echocardiography within
72 h upon admission. Ejection fraction was calculated according to
biplane Simpson method.
2.6. End points
The primary end point was the proportion of patients whowere free
of congestion at day 3 (deﬁned as jugular venous pressure of b8 cm, no
orthopnea and no peripheral edema).
Two safety outcomes (pCr change between day 1 and day 3 plus
potassium change between day 1 and day 3) were considered.
Secondary end points included changes in: body weight; NTproBNP
levels; microalbuminuria; serum sodium; ionized calcium; serum
magnesium; hsTnT; urinary sodium, potassium, urea; and the propor-
tion of patients: taking oral furosemide at day 3; with increase in
pCr ≥ 0.3 mg/dL from day 1 to day 3; and with hyper or hypokalemia
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Comparison between groupswas performed using parametric or non-
parametric tests, as appropriate. Continuous variables are expressed as
mean (standard deviation, SD) or median (inter-quartile range, IQR).
Categorical variables are expressed in absolute numbers (no.) and
proportions.
Association between different variables was tested by univariate
analysis.
Signiﬁcant association was deﬁned by a p value ≤ 0.05.
Statistical analysis was performed using SPSS software (version 19,
Chicago, IL, USA).
3. Results
The pre-speciﬁed duration of the enrolment period was one year
and during that time we enrolled a total of 100 patients. Fifty patients
were allocated to the treatment group. Despite the study protocol
referred a range spironolactone dose of 50 to 100 mg/d, one patient
had 200 mg at day 1. The mean ± (SD) spironolactone dose at day 1
was 94.5 ± 23.3 mg and at day 3 was 62.7 ± 24.3 mg.
Baseline characteristics of patients in each of the treatment groups
are shown in Table 1. Patients in the control group were signiﬁcantly
older (mean ± (SD), 78.8 ± 9.3 vs. 73.2 ± 11.7 years; p = 0.01). The
study groups were well balanced in most clinical characteristics,
namely: gender, ejection fraction, baseline HF medications (except for
beta-blockers, more common in control group — no. (%): 26 (52) vs.
10 (20); p = 0.001), comorbidities [11], and risk stratiﬁcation for
in-hospital mortality [12,13]. All patients were in New York Heart
Association (NYHA) class IV upon admission.
Analyzed end-points are shown in Table 2. Patients in the treatment
group had a signiﬁcant respiratory rate (cycles/minute) reduction at
day 3 (median [IQR], 20 [2] vs. 18 [3]; p b 0.001). No differences were
observed in weight reduction, heart rate and systolic blood pressure
(SBP). No patient developed hypotension (SBP b 90 mmHg).
A greater proportion of patients in the treatment group was free of
congestion at day 3: no edema (32% vs. 66%; p = 0.001), no rales
(24% vs. 66%; p b 0.001), jugular venous pressure (JVP) ≤ 8 cm (90%
vs. 100%; p = 0.02) and no orthopnea (76% vs. 96%; p = 0.004). In
addition, a signiﬁcantly higher proportion of patients were switched
to oral furosemide at day 3 (44% vs. 82%; p b 0.001)— Graph 1. Furose-
mide dose was not signiﬁcantly different in patients who remained on
i.v. administration. ACEi and BB doses did not differ between study
groups.
Worsening renal function (increase in pCr ≥ 0.3 mg/dL from day 1
to day 3) was more frequent in control group (20% vs. 4%; p = 0.038).
Indirectmarkers of glomerular damagewere not signiﬁcantly differ-
ent between groups, but the treatment group appeared to have less
glomerular damage after 3 days of treatment i.e. greater albuminuria
reduction (median [IQR], — 7.3 [45.8] vs. 10.1 [71.2]; p = 0.32), and
lower albuminuria ratio (median [IQR], 0.9 [0.8] vs. 0.7 [0.7]; p = 0.19).
Fractional excretion of sodium (FENa) and urea (FEUr) did not differ
between groups, however urine sodium to potassium (UNa/K) ratio
signiﬁcantly increased at day 3 in the spironolactone group (median
[IQR], 2.1 [3.1] vs. 4.0 [3.9]; p = 0.007).
Serum potassium (K+) levels did not differ signiﬁcantly between
groups — Graph 2. No patients developed hyperkalemia (serum
potassium ≥ 5.5 mmol/L). More patients in the control group devel-
oped hypokalemia (serum potassium ≤ 3.5 mmol/L) but no signiﬁcant
differences were found (26% vs. 14%; p = 0.13).
Plasma NTproBNP had a signiﬁcant decrease in spironolactone
group at day 3 (median [IQR], 2488 [4579] vs. 1555 [1832]; p =
0.05) — Graph 3.
No signiﬁcant differences were observed in hsTnT (median [IQR],
— 0.0005 [0.01] vs. 0.001 [0.01]; p = 0.57).agonism in acutely decompensated chronic heart failure, Eur J Intern
Table 1
Baseline characteristics of the study population.
Control
group
Spironolactone
group
p value
Age (yrs) 78.8 ± 9.3 73.2 ± 11.7 0.01
Male sex — no. (%) 17 (34) 22 (44) 0.31**
Ejection Fraction (%) 45.5 ± 10.7 41.4 ± 12.4 0.08
Left Atrial Size (mm) 47.4 ± 5.3 46.3 ± 7.1 0.40
Charlson Index (pts) 6, 1 ± 1.1 5.9 ± 0.9 0.38
HgB (g/dL) 12.2 ± 1.8 12.7 ± 2.3 0.22
Albumin (mg/dL) 3.7 ± 0.4 3.6 ± 0.4 0.63
TSH (mUI/L) 2.8 ± 3.0 2.6 ± 2.8 0.79
Etiology of Heart Failure — no. (%)
Ischemic 24 (48) 26 (52) 0.69**
Non-Ischemic 26 (52) 24 (48) 0.84**
Basal NYHA class — no. (%)
II 41 (82) 44 (88) 0.40**
III 9 (18) 6 (12) 0.40**
History of Atrial Fibrillation
or Flutter— no. (%)
34 (68) 25 (50) 0.07**
Outpatients Medications — no. (%)
Furosemide 37 (74) 35 (70) 0.65**
ACE Inhibitors 24 (48) 18 (36) 0.22**
Beta-Blockers 26 (52) 10 (20) 0.001**
Outpatients Oral Dose (mg)
Furosemide 69.2 ± 37.8 68 ± 30 0.89
ACE Inhibitors 5 ± 3 4.3 ± 2.5 0.43
Beta-Blockers 4.4 ± 2.7 4.5 ± 1.1 0.90
Adhere: in-hospital mortality risk – no. (%)
Low 44 (88) 40 (80) 0.27**
Intermediate 2 2 (4) 3 (6) 0.65**
Intermediate 3 4 (8) 7 (14) 0.34**
Effect: heart failure mortality risk prediction – no. (%)
Low 4 (8) 8 (16) 0.22**
Intermediate 27 (54) 25 (50) 0.69**
High 18 (36) 17 (34) 0.83**
BMI ≥ 30 (kg/m2) — no. (%) 14 (28) 19 (38) 0.29**
Diabetes mellitus— no. (%) 25 (50) 20 (40) 0.31**
Glycated hemoglobin (%) 6.9 ± 0.7 7.1 ± 1.2 0.43
Obstructive sleep apnea Syndrome — no. (%) 5 (10) 13 (26) 0.32**
Non-Invasive ventilation — no. (%) 7 (14) 10 (20) 0.42**
AHF precipitant (n)
Undertreatment 34 (68) 29 (58) 0.30**
Dysrythmia 10 (20) 9 (18) 0.80**
Non-compliance 6 (12) 8 (16) 0.56**
NSAIDs 0 4 (8) 0.04**
Continuous variables are presented as mean value ± standard deviation [SD], p value.
Categorical variables are presented as absolute number (%), p value. **Chi-square test.
HgB = hemoglobin; ACE = angiotensin-converting enzyme; BMI = Body Mass Index;
NYHA = New York Heart Association; AHF = Acute Heart Failure; NSAID = Non-
Steroidal Anti-Inﬂammatory Drug.
Table 2
Study End-Points.
Control
group
Spironolactone
group
p Value
Heart rate (beats/min)
Day 1 91.2 ± 24.7 96.1 ± 23.9 0.30
Day 3 74.9 ± 12.4 77.9 ± 11.4 0.20
SBP (mm Hg)
Day 1 140.5 ± 23.9 139 ± 27.9 0.80
Day 3 122 ± 15.6 121.9 ± 16.8 0.97
RR (cycles/min)
Day 1 35 [5] 33.5 [6] 0.90*
Day 3 20 [2] 18 [3] b 0.001*
BMI (kg/m2)
Day 1 29.3 ± 5.7 29.5 ± 6.6 0.90
Day 3 28.1 ± 5.4 27.7 ± 6.6 0.76
Peripheral edema – no. (%)
Day 1 50 (100) 50 (100)
Day 3 34 (68) 17 (34) 0.001**
Rales — no. (%)
Day 1 50 (100) 50 (100)
Day 3 38 (76) 17 (34) b0.001**
JVP ≥ 8 cm— no. (%)
Day 1 32 (64) 28 (56) 0.41**
Day 3 5 (10) 0 0.02**
Orthopnea — no. (%)
Day 1 50 (100) 50 (100) –
Day 3 12 (24) 2 (4) 0.004**
pCr (mg/dL) 1.15 ± 0.27 1.03 ± 0.29 0.026
Day 1 1.23 ± 0.43 1.06 ± 0.33 0.035
Day 3
pCr change (mg/dL)
Day 3 — day 1 0.075 ± 0.3 0.038 ± 0.17 0.47
Increase in pCr ≥ 0.3 mg/dL
from Day 1 to day 3 — no. (%)
10 (20) 2 (4) 0.038**
pUrea 59.32 ±
22.27
51.10 ± 18.63 0.048
Day 1 67.08 ±
27.09
57.54 ± 23.03 0.061
Day 3
pUrea change (mg/dL)
Day 3 — day 1 7.7 ± 22.9 6.4 ± 17.9 0.75
Albuminuria (mg/g) 73.50 [196.5] 54.05 [203.7] 0.521*
Day 1 60.16 [203] 27.9 [80.2] 0.118*
Day 3
Albuminuria change (mg/g)
Day 3 — day 1 −7.3 [45.8] −10.1 [71.2] 0.32*
Albuminuria ratio 0.9 [0.8] 0.7 [0.7] 0.19*
Day 3/day 1
FENa (%)
Day 1 1.4 [2] 2.4 [3.5] 0.24*
Day 3 1.2 [2] 1.6 [2.5] 0.27*
FEUr (%)
Day 1 38.9 ± 12.7 38.2 ± 11.1 0.47
Day 3 39.5 ± 13.2 37.1 ± 10.5 0.31
UNa/K Ratio
Day 1 2.7 [3.7] 3.6 [4.7] 0.18*
Day 3 2.1 [3.1] 4.0 [3.9] 0.007*
Serum potassium (mmol/L)
Day 1 4.1 ± 0.4 4.0 ± 0.6 0.33
Day 3 3.9 ± 0.5 4.1 ± 0.5 0.15
Hypokalemia (mmol/L) at day 3— no. (%) 13 (26) 7 (14) 0.13**
Serum sodium (mmol/L)
Day 1 140 [7] 141 [4] 0.9*
Day 3 141.2 ± 4.3 140.2 ± 3.5 0.2
Serum Ionized calcium (mmol/L)
Day 1 1.2 [0.1] 1.2 [0.1] 0.6*
Day 3 1.2 [0.1] 1.2 [0.1] 0.1*
(continued on next page)
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4. Discussion
Our study strongly suggests that the use of spironolactone in ADCHF
patients is safe. Furthermore, spironolactone treatment was also associ-
ated with an earlier resolution of symptoms and signs of congestion, as
well as a more pronounced NTproBNP reduction.
Baseline clinical characteristicswerewell balanced between the two
groups. Although control participants were older than those in the
treatment group, that difference did not signiﬁcantly change the
mortality risk prediction scores. The control group had also higher pro-
portion of baseline beta-blockers prescription. However, during hospi-
talization the beta-blocker treatment did not differ between groups.
The concern about hyperkalemia erroneously precludes the judi-
cious prescription of MRAs in many clinical settings. Our study ﬁndings
show that this therapy is safe in ADCHF as the use of spironolactone inPlease cite this article as: Ferreira JP, et al, Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure, Eur J Intern
Med (2013), http://dx.doi.org/10.1016/j.ejim.2013.08.711
Table 2 (continued)
Control
group
Spironolactone
group
p Value
Serum Magnesium (mmol/L)
Day 1 0.84 [0.1] 0.8 [0.1] 0.2*
Day 3 0.87 [0.1] 0.85 [0.1] 0.6*
ProBNP (pg/ml)
Day 1 3102 [6408] 2701 [3541] 0.17*
Day 3 2488 [4579] 1555 [1832] 0.05*
TnT (ng/mL)
Day 1 0.034 [0.035] 0.03 [0.032] 0.5*
Day 3 0.032 [0.036] 0.029 [0.028] 0.3*
TnT reduction (ng/mL)
Day 3–day 1 −0.0005
[0.01]
−0.001 [0.01] 0.57*
CkMB (UI/L)
Day 1 15.5 [9] 14 [9] 0.14*
Day 3 14 [8] 12 [8] 0.13*
CkMB reduction (UI/mL)
Day 3–day 1 −1.7 ± 6.2 −2.3 ± 4.3 0.63
IV furosemide dose (mg)
Day 1 80 [20] 80 [30] 0.86*
Day 3 60 [20] 60 [30] 0.22*
Oral furosemide at day 3 — no. (%) 22 (44) 41 (82) b 0.001**
ACE Inhibitors dose (mg)
Day 1 2.5 [3.8] 2.5 [2.5] 0.75*
Day 3 2.5 [3.8] 2.5 [3.8] 0.72*
ACE Inhibitors — no. (%)
Day 1 19 (38) 25 (50) 0.20**
Day 3 30 (60) 31 (62) 0.80**
Beta-blockers dose (mg)
Day 1 2.5 [0] 2.5 [2.5] 0.95*
Day 3 2.5 [2.5] 2.5 [1.25] 0.46*
Beta-blockers — no. (%)
Day 1 21 (42) 16 (32) 0.30**
Day 3 27 (54) 30 (60) 0.50**
Length of stay (days) 9 [5] 8 [5] 0.8*
Continuous variables are presented as mean value ± standard deviation [SD], p value or
median [inter-quartile range, IQR], p value. Categorical variables are presented as
absolute number (%), p value. *Non-parametric test; **Chi-square test.
SBP = systolic blood pressure; RR = respiratory rate; JVP = jugular venous pressure;
BMI = Body Mass Index; PaO2/FiO2 = partial pressure arterial oxygen/fraction inspired
oxygen; pCr = plasma creatinine; FENa = spot urine fractional excretion of sodium;
FEUr = spot urine fractional excretion of urea; UNa/K = urinary sodium to potassium
ratio; proBNP = N-terminal pro brain natriuretic peptide; TnT = high-sensitivity tropo-
nin T; CkMB = creatine kinase-MB; ACE = angiotensin-converting enzyme.
p = 0,001
p < 0,001
p =
-40
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Graph 1. Changes in congestive signs and patients taking oral furo
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The concomitant use of i.v. diuretics with kaliuretic properties could
contributed to the absence of hyperkalemia [19]. In clinical trials enroll-
ing chronic HF patients, MRAs were well tolerated when patients with
pCr N 2.5 mg/dL and serum potassium N 5 mmol/L were excluded
[2,20]. Still regarding thepotassium levels,we observed a trend to hypo-
kalemia in the control group compared to the treatment group. This re-
sult is concordant with a previous study where the risk of hypokalemia
was signiﬁcantly reduced among patients receivingMRAs [3]. Reducing
the risk of hypokalemia is a signiﬁcant issue due to the fact that a potas-
sium level below 4.0 mmol/L has been associatedwith an increased risk
of death from any cause among patients with systolic heart failure [21].
Moreover, worsening renal function occurred more frequently in
control group. Previous studies suggest that high i.v. diuretic dose is as-
sociated with worsening renal function in the short term [17,18]. The
frequent congestion status of ADHF and the diuretic therapy activate
the RAAS and SNS, which induce renal arteriolar vasoconstriction,
endothelial dysfunction and increased tubular reabsorption of sodium
and urea [18]. The spironolactone diuretic and renoprotective potential
can contribute to these clinical important ﬁndings.
We found that patients submitted to high dose spironolactone as
add-on to standard AHF therapy had a faster resolution of congestive
signs and an earlier switch to oral furosemide. The diuretic effect of
spironolactone and possibly the attenuation of the pathological effects
of mineralocorticoid receptor (MR) activation [14,15] could explain
these ﬁndings. In a previous study including 21 AHF patients with insuf-
ﬁcient response to loop diuretics, 16 patients (76%) were submitted to
100 mg spironolactone once a day for 7 days in addition to high-dose
loop diuretic (10 mg oral bumetanide) in combination with the maxi-
mum tolerable dose of an ACEi. Spironolactone coadministration was
highly effective in 13 of 16 patients (81%). Marked natriuresis and di-
uresis were achieved within the next week of treatment, and HF symp-
toms decreased or disappeared [16]. Despite the earlier resolution of
congestive signs found in the treatment group, no signiﬁcant differences
were observed in body weight change; this ﬁnding can be explained by
the multiple patterns of congestion found i.e., many patients had left
heart predominance with little weight change, and patients with right
heart predominance presented with different levels of congestion.
These differences (not discriminated in the study) may contribute for
this apparent mismatch.
Consistent with the faster resolution of congestive signs and with
the preservation of the renal function discussed above, we documented
a signiﬁcant reduction in NTproBNP within the spironolactone group.
This is a notable ﬁnding since natriuretic peptides have shown to 0,02
p = 0,004
p < 0,001
 8 cm Orthopnea Oral Furosemide at 
Day 3
pironolactone Group
semide at day 3 (%) in the control and spironolactone groups.
agonism in acutely decompensated chronic heart failure, Eur J Intern
Graph 2. Changes in serum potassium (K+) from day 1 to day 3 in the control and spironolactone groups.
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the severity of left ventricular dysfunction, and are robust prognostic
predictors in HF [22–26].
Despite no signiﬁcant differences were found, patients in the treat-
ment group had greater albuminuria reduction during the treatment
period. Albuminuria is an important predictor of adverse cardiovascular
events in various populations and MRAs have been shown to attenuate
vascular hypertrophy and reduce albuminuria [27,28]. The improve-
ment of this surrogate endpoint gives additional insight on possible
beneﬁts of MRA in ADCHF.
Mineralocorticoid receptor antagonists have been observed to stim-
ulate natriuresis and improve diuretic responsiveness in patients with
HF [29]. Although FENa did not differ between groups, urine sodium
to potassium (UNa/K) ratio signiﬁcantly increased at day 3 in the
spironolactone group. Elevation of UNa/K ratio has been demonstrated
to be a translatable biomarker of MRA effect [30]. These ﬁndings were
reproducible in our study. Future research should be conducted to vali-
date this promising neurohormonal biomarker in the ADHF setting.
Several limitations in this study should be noted. Firstly, given that
no randomization or concealed allocation was performed, we cannot
exclude a selection bias, which can impact on our conclusions' external
validity. Secondly, the assistant physicians performed the congestive
signs assessment, therefore, we cannot exclude an ascertainment bias.
This can affect the internal validity of the comparison of subjective out-
comes such as congestive signs or symptoms. Though, we had includedGraph 3. Changes in mean plasma levels of NT pro-brain natriuretic peptide (N
Please cite this article as: Ferreira JP, et al, Mineralocorticoid receptor ant
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ed by this bias and appear to be consistent with the earlier resolution of
the congestive signs in the treatment group. Lastly, our study was
underpowered to detect the differences of the expected low rate of ad-
verse events between groups. Thus, our safety data should be viewed as
exploratory.
5. Conclusion
Our study shows that treating ADHF patients with spironolactone was
safe. It was also associated with an earlier resolution of the congestive
signs and with a more pronounced NTproBNP reduction. Despite its ex-
ploratory nature, our study highlights the need to improve the treatment
of ADHF andpoints out the direction of future investigation towardsMRAs.
Learning points
• Mineralocorticoid receptor antagonists (MRAs) used in acutely
decompensated chronic heart failure (ADCHF)may improve congestion
through diuretic effect and prevention of neurohormonal activation.
• High dose MRAs (±100 mg Spironolactone) used in ADCHF is safe: is
not associated with renal injury and/or hyperkalemia, but may prevent
loop diuretic induced hypokalemia.
• Congestion relief is translated into a more pronounced natriuretic pep-
tide reduction.TproBNP) from day 1 to day 3 in the control and spironolactone groups.
agonism in acutely decompensated chronic heart failure, Eur J Intern
6 J.P. Ferreira et al. / European Journal of Internal Medicine xxx (2013) xxx–xxxConﬂict of interest
The authors have no conﬂicts to disclose.Acknowledgements
The authors acknowledge the lab technicians, speciallyMr. Fernando
Santos for technical assistance and to all physicians collaborating in the
study.References
[1] Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical
model and beyond. Circulation 2005:2837–49 [United States].
[2] Pitt B, RemmeW, Zannad F, Neaton J, Martinez F, Roniker B, et al. a selective aldoste-
rone blocker, in patientswith left ventricular dysfunction aftermyocardial infarction.
N Engl J Med 2003:1309–21 [United States: 2003 Massachusetts Medical Society].
[3] Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J
Med 2011;364:11–21.
[4] Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol
2009:557–73 [United States].
[5] Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: thera-
peutic potential in acute heart failure syndromes. Eur Heart J 2011:2626–33 [England].
[6] Aronson D, Burger AJ. Neurohormonal prediction of mortality following admission
for decompensated heart failure. Am J Cardiol 2003:245–8 [United States].
[7] Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid
nongenomic effects of aldosterone on the renal vasculature in humans. Hyperten-
sion 2006:650–5 [United States].
[8] Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction
in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci
(Lond) 2002;103:425–31.
[9] De Luca L, Fonarow GC, Adams Jr KF, Mebazaa A, Tavazzi L, Swedberg K, et al. Acute
heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy.
Heart Fail Rev 2007;12:97–104.
[10] Struthers AD. Aldosterone: cardiovascular assault. Am Heart J 2002:S2–7 [United
States].
[11] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prog-
nostic comorbidity in longitudinal studies: development and validation. J Chronic
Dis 1987;40:373–83.
[12] Fonarow GC, Adams Jr KF, AbrahamWT, Yancy CW, BoscardinWJ. Risk stratiﬁcation
for in-hospital mortality in acutely decompensated heart failure: classiﬁcation and
regression tree analysis. JAMA 2005:572–80 [United States].
[13] Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among
patients hospitalized for heart failure: derivation and validation of a clinical model.
JAMA 2003:2581–7 [United States].Please cite this article as: Ferreira JP, et al, Mineralocorticoid receptor ant
Med (2013), http://dx.doi.org/10.1016/j.ejim.2013.08.711[14] van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart
failure refractory to high-dose loop diuretic and low-dose angiotensin-converting
enzyme inhibitor. Am J Cardiol 1993;71:21A–8A.
[15] Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical
outcomes in the eplerenone post-acute myocardial infarction heart failure efﬁcacy
and survival study (ephesus). Circulation 2008:1643–50 [United States].
[16] Felker GM, Lee KL, Bull DA, Redﬁeld MM, Stevenson LW, Goldsmith SR, et al. Di-
uretic strategies in patients with acute decompensated heart failure. N Engl J Med
2011;364:797–805.
[17] Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship
between heart failure treatment and development of worsening renal function
among hospitalized patients. Am Heart J 2004:331–8 [United States].
[18] Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or
pathogenetic factor?J Am Coll Cardiol 2006:1–8 [United States].
[19] Sanjay S, Annigeri RA, Seshadri R, Rao BS, Prakash KC,ManiMK. The comparison of the
diuretic andnatriuretic efﬁcacy of continuous andbolus intravenous furosemide in pa-
tients with chronic kidney disease. Nephrology (Carlton) 2008:247–50 [Australia].
[20] Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of
spironolactone on morbidity and mortality in patients with severe heart
failure. Randomized aldactone evaluation study investigators. N Engl J Med
1999;341:709–17.
[21] Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, et al. A
propensity-matched study of the association of low serum potassium levels and
mortality in chronic heart failure. Eur Heart J 2007:1334–43 [England].
[22] Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, Pouleur H, et al. Direct
comparison between endothelin-1, n-terminal proatrial natriuretic factor, and
brain natriuretic peptide as prognostic markers of survival in congestive heart
failure. J Card Fail 2000:201–7 [United States].
[23] Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, et al. N-terminal
proatrial natriuretic factor. An independent predictor of long-term prognosis after
myocardial infarction. Circulation 1994;89:1934–42.
[24] Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of
spironolactone on plasma brain natriuretic peptide and left ventricular remodeling
in patients with congestive heart failure. J Am Coll Cardiol 2001:1228–33 [United
States].
[25] Metra M, Nodari S, Parrinello G, Specchia C, Brentana L, Rocca P, et al. The role of plas-
ma biomarkers in acute heart failure. Serial changes and independent prognostic value
of nt-probnp and cardiac troponin-t. Eur J Heart Fail 2007:776–86 [Netherlands].
[26] Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-
brain natriuretic peptide predicts outcome after hospital discharge in heart failure
patients. Circulation 2004:2168–74 [United States].
[27] Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the
good, the bad, and the ugly? Pﬂugers Arch 2009;458:231–46.
[28] Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond)
2007:267–78 [England].
[29] Hensen J, AbrahamWT, Durr JA, Schrier RW. Aldosterone in congestive heart failure:
analysis of determinants and role in sodium retention. Am J Nephrol 1991;11:441–6.
[30] Eudy RJ, Sahasrabudhe V, Sweeney K, Tugnait M, King-Ahmad A, Near K, et al. The
use of plasma aldosterone and urinary sodium to potassium ratio as translatable
quantitative biomarkers of mineralocorticoid receptor antagonism. J Transl Med
2011:180 [England].agonism in acutely decompensated chronic heart failure, Eur J Intern
